We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

60 hedge funds and large institutions have $31M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 22

3% less funds holding

Funds holding: 62 → 60 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

31% less capital invested

Capital invested by funds: $45.1M → $31M (-$14.1M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
60
Holders Change
-2
Holders Change %
-3.23%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
7
Increased
22
Reduced
22
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.63M
2
WCM
Wedge Capital Management
North Carolina
+$1.28M
3
MF
Magnetar Financial
Illinois
+$782K
4
BFM
Boothbay Fund Management
New York
+$193K
5
Renaissance Technologies
Renaissance Technologies
New York
+$167K

Top Sellers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
-$5.74M
2
CCM
CAAS Capital Management
New York
-$2.62M
3
Marshall Wace
Marshall Wace
United Kingdom
-$1.1M
4
SSA
Schonfeld Strategic Advisors
New York
-$819K
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$668K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$7K – – –
PCM
52
Penserra Capital Management
California
$6K +$5.37K +931 +171%
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
$6K +$8.79K +1,525 New
OSAM
54
O'Shaughnessy Asset Management
Connecticut
$5K – – –
AIP
55
Ameritas Investment Partners
Nebraska
$3K – – –
PNC Financial Services Group
56
PNC Financial Services Group
Pennsylvania
$3K – – –
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$2K – – –
PAM
58
Panagora Asset Management
Massachusetts
$1K -$24K -4,163 -95%
Daiwa Securities Group
59
Daiwa Securities Group
Japan
$1K -$882 -153 -52%
AIG
60
American International Group
New York
$30 -$2.06K -357 -5%
SSA
61
Schonfeld Strategic Advisors
New York
– -$819K -151,400 Closed
GC
62
Globeflex Capital
California
– -$532K -98,247 Closed
Squarepoint
63
Squarepoint
New York
– -$314K -58,102 Closed
PP
64
PDT Partners
New York
– -$71K -13,165 Closed
AIM
65
Alambic Investment Management
California
– -$68K -12,516 Closed
MAM
66
Meeder Asset Management
Ohio
– -$61K -11,216 Closed
SO
67
STRS Ohio
Ohio
– -$14K -2,600 Closed
UBS Group
68
UBS Group
Switzerland
– -$3K -600 Closed
SSB
69
Sandy Spring Bank
Maryland
– -$1K -100 Closed
1 2
3

RVLP Hedge Fund Activity: Q4 2020 in Review

60 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2020, worth a combined $31M — down 31% from $45.1M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of RVLP and 7 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 22 added.

The largest buyer was Morgan Stanley, adding an estimated $5.63M. The largest seller was DG Capital Management, cutting an estimated $5.74M.

  • 60 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2020, down from 62 in Q3 2020.
  • Funds reported $31M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2020, down 31% quarter-over-quarter.
  • 7 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2020 and 9 closed out, a net change of -2 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2020 was Morgan Stanley, an estimated $5.63M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2020 was DG Capital Management, an estimated $5.74M sold.

Based on aggregated 13F filings for Q4 2020.